Todd Brady, Aldeyra Therapeutics CEO
'Approvability has been put to bed': Aldeyra says eye drop clears three dry eye signals en route to FDA
Aldeyra’s attempt at treating dry eye disease has seen a few ups and downs in recent years, but the biotech’s sight to approval got a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
